Advertisement

Radionuclide Methods for the Evaluation of Ventricular Function and Thrombolytic Therapy

  • Paolo Marzullo
  • Alessia Gimelli
  • Antonio L’Abbate
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 158)

Abstract

Nuclear imaging of the heart is widely applied in the diagnosis and care of all forms of cardiac diseases. In this chapter we discuss the application of radioisotopic techniques in the evaluation of different drugs used in patients with coronary artery disease. Furthermore, we indicate for each drug the main results published in literature and the limitations that should be considered when the radioisotopic approach is used.

Keywords

Ejection Frac Nuclear Cardiology Thrombolytic Therapy Regional Wall Motion Peak Exercise 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marzullo P, Parodi O, Sambuceti G, Marcassa C, Gimelli A, Bartoli M, Neglia D, L’Abbate A. Does the myocardium become “stunned” after episodes of angina at rest, angina on effort and coronary angioplasty? Am J Cardiol 1993;71:1045–1051.PubMedCrossRefGoogle Scholar
  2. 2.
    Harper R, Claxton H, Middlebrook K, Anderson S, Pitt A. Acute and chronic effects of prazosin in severe congestive heart failure (abstract). Circulation 1979;60(Suppl II):H129.Google Scholar
  3. 3.
    Steele PP, Rainwater J, Jensen D, Vogel RA, Battock D. Isosorbide dinitrate-induced improvement in left ventricular ejection fraction during exercise in coronary artery disease. Chest 1978;74:526–531.PubMedCrossRefGoogle Scholar
  4. 4.
    Olson GW, Logic JR, Whitlow PL. Comparative vasodilator responses in nifedipine, hydralazine and nitroprusside in patients with congestive heart failure (abstract). J Am Coll Cardiol 1984;3:479.Google Scholar
  5. 5.
    Koch-Weser J. Hydralazine. N Engl J Med 1976;295:320–323.PubMedCrossRefGoogle Scholar
  6. 6.
    McAnulty JH, Hattenhauer MT, Rosch J, Kloster FE, Rahimtoola SH Improvement in left ventricular wall motion following nitroglycerin. Circulation 1975;51:140–145.PubMedCrossRefGoogle Scholar
  7. 7.
    Slutsky R, Battler A, Gerber K, Gordon D, Froelicher V, Karliner J, Ashburn W. Effects of nitrates on left ventricular size and function during exercise: Comparison of sublingual nitroglycerin and nitroglycerin paste. Am J Cardiol 1980;45:831–840.PubMedCrossRefGoogle Scholar
  8. 8.
    Hetch HS, Karahalios SE, Schnugg SJ, Ormiston JA, Hopkins JN, Rose JG, Singh BN. Improvement in supine bycicle exercise performance in refractory congestive heart failure after isosorbide dinitrate: Radionuclide and hemodynamic evaluation of acute effects. Am J Cardiol 1982;49:133–140.CrossRefGoogle Scholar
  9. 9.
    Marzullo P, Parodi O, Schelbert HR, L’Abbate A. Regional myocardial dysfunction in patients with angina at rest and response to isosorbide dinitrate assessed by phase analysis of radionuclide ventriculograms. J Am Coll Cardiol 1984;3:1357–1366.PubMedCrossRefGoogle Scholar
  10. 10.
    Shah PK, Abdulla A, Pichler M, Shellock F, Berman D, Singh BN, Swan HJC. Effects of nitroprusside-mduced reduction of elevate preload and afterload on global and regional ventricular function in acute myocardial infarction. Am Heart J 1983;105:531–542.PubMedCrossRefGoogle Scholar
  11. 11.
    Bodenheimer MM, Ramanathan K, Banka VS, Helfant RH. Effect of progressive pressure reduction with nitroprusside on acute myocardial infarction in humans. Determination of optimal afterload. Ann Intern Med 1981;94:435–439.PubMedCrossRefGoogle Scholar
  12. 12.
    Vidt DG, Bravo EL, Fouad FM. Captopril. N Engl J Med 1982;306:214–219.PubMedCrossRefGoogle Scholar
  13. 13.
    Awan NA, Evenson MK, Needham KE, Win A, Mason DT. Efficacy of oral-angiotensin-converting enzyme inhibition with Captopril therapy in severe chronic normotensive congestive heart failure. Am Heart J 1981;101:22–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Massie BM, Kramer BL, Topic N. Long term Captopril therapy for chronic congestive heart failure. Am J Cardiol 1984;53:1316–1320.PubMedCrossRefGoogle Scholar
  15. 15.
    Kelbaek H, Agner E, Wroblenski H, Madsen PV, Marving J. Angiotensin converting enzyme inhibition at rest and during exercise in congestive heart failure. Eur Heart J 1993;14:692–695.PubMedCrossRefGoogle Scholar
  16. 16.
    Massie BM, Kramer BL, Topic N, Henderson SG. Hemodynamic and radionuclide effects of acute Captopril therapy for heart failure: Changes in left and right ventricular volumes and function at rest and during exercise. Circulation 1982;65:1374–1381.PubMedCrossRefGoogle Scholar
  17. 17.
    Colucci WS, Wynne J, Holman BL, Braunwald E. Long-term therapy of heart failure with prazosin: A randomized double-blind trial. Am J Cardiol 1980,45:337–344.PubMedCrossRefGoogle Scholar
  18. 18.
    Colucci WS, Holman BL, Wynne J, Carabello B, Malacoff R, Grossman W, Braunwald E. Improved right ventricular function and reduced pulmonary vascular resistance during prazosin therapy of congestive heart failure. Am J Med 1981;71.75–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Goldman SA, Johnson LL, Escala E, Cannon PJ, Weiss MB. Improved exercise ejection fracrion with long term prasozin therapy in patients with heart failure. Am J Med 1980;68:36–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Fouad FM, Tarazi RC, Bravo EL, Hart NJ, Castle LW, Salcedo EE. Long-term control of congestive heart failure with Captopril. Am J Cardiol 1982;49:1489–1496.PubMedCrossRefGoogle Scholar
  21. 21.
    Markham RV, Corbett JR, Gilmore A, Pettinger WA, Firth BG. Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled study. Am J Cardiol 1983;51:1346–1352.PubMedCrossRefGoogle Scholar
  22. 22.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685–691.CrossRefGoogle Scholar
  23. 23.
    Captopril Multicenter Research Group. A placebo-controlled trial of Captopril in refractory chronic congestive heart failure. Am J Coll Cardiol 1983;2:775–763.Google Scholar
  24. 24.
    Port S, Cobb FR, Jones RH. Effects of propranolol on left ventricular function in normal men. Circulation 1980;61:358–366.PubMedCrossRefGoogle Scholar
  25. 25.
    Marshall RC, Wisenberg G, Scheiben HR, Henze E. Effect of oral propranolol on rest, exercise and post-exercise left ventricular performance in normal subjects and patients with coronary artery disease. Circulation 1981;63:572–579.PubMedCrossRefGoogle Scholar
  26. 26.
    Bonow RO, Leon MB, Rosing DR, Kent KM, Lipson LC, Bacharach SL, Green MV, Epstein SE. Effects of verapamil and propranolol on left ventricular systolic function and diastolic filling in patients with coronary artery disease: Radionuclide angiographic studies at rest and during exercise. Circulation 1982;65:1337–1350.PubMedCrossRefGoogle Scholar
  27. 27.
    Josephson MA, Hecht HS, Hopkins J, Guerrero J, Singh BN. Comparative effects of oral verapamil and propranolol on exercise-induced myocardial ischemia and energetics in patients with coronary artery disease: Single-blind placebo crossover evaluation using radionuclide ventriculography. Am Heart J 1982; 103:978–984.PubMedCrossRefGoogle Scholar
  28. 28.
    Bourdillon PD, Canepa-Anson R, Richards AF. Hemodynamic effects of intravenous metoprolol. Am J Cardiol 1979;44:1195–1200.PubMedCrossRefGoogle Scholar
  29. 29.
    Pfisterer M, Glaus L, Burkart F. Comparative effects of nitroglycerin, nifedipine and metoprolol on regional left ventricular function in patients with one-vessel coronary disease. Circulation 1983;67:291–301.PubMedCrossRefGoogle Scholar
  30. 30.
    Fouad FM, Tarazi RC, Bravo EL. Relation of cardiovascular response to the hypotensive effect of metoprolol. Am Heart J 1982;104:803–811.PubMedCrossRefGoogle Scholar
  31. 31.
    Kalischer AL, Johnson LL, Johnson YE, Stone J, Feder JL, Escala E, Cannon PJ. Effects of propranolol and timolol on left ventricular volumes during exercise in patients with coronary artery disease. J Am Coll Cardiol 1984;3:210–218.PubMedCrossRefGoogle Scholar
  32. 32.
    Manyari DE, Kostuk WJ, Carruthers GS, Johnston DJ, Purves P. Pindolol and propranolol in patients with angina pectoris and normal or near-normal ventricular function. Lack of influence of intrinsic sym-phathomimetic activity on global and segmental left ventricular function assessed by radionuclide ventriculography. Am J Cardiol 1983;51:427–433.PubMedCrossRefGoogle Scholar
  33. 33.
    Plotnick GD, Fisher ML, Wohl B, Hamilton JH, Hamilton BP. Improvement in depressed cardiac function in hypertensive patients during pindolol treatment. Am J Med 1984;76:25–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Le Winter MM, Curtis GP, Engler RL, Shabetai R, Verba J. Effects of equiblocking doses of nadodol and propranolol on left ventricular performance. Clin Pharmacol Ther 1979;26:162–168.PubMedGoogle Scholar
  35. 35.
    Fouad FM, Slominski MJ, Tarazi RC, Gallagher JH. Alterations in left ventricular filling with beta-adrenergic blockade. Am J Cardiol 1983;51:161–164.PubMedCrossRefGoogle Scholar
  36. 36.
    Amende I, Simon R, Hood WP, Lichtlen PR. The effects of beta-blocker atenolol and nitroglycerin on left ventricular function and geometry in man. Circulation 1979;60:836–848.PubMedCrossRefGoogle Scholar
  37. 37.
    Godenir JP, Amor R, Cherrier F, Houppe JP, Karcher G, Bertrand A. Atenolol in unstable angina. Clinical results and assessment of left ventricular function by radionuclide angiography. Drugs 1983,25(Suppl 2):172–180.CrossRefGoogle Scholar
  38. 38.
    Sorensen SG, Ritchie JL, Caldwell JH, Hamilton GW, Kennedy JW. Serial exercise radionuclide angiography. Validation of count-derived changes in cardiac output and quantitation of maximal exercise ventricular volume change after nitroglycerin and propranolol in normal men. Circulation 1980;61:600–609.PubMedCrossRefGoogle Scholar
  39. 39.
    Frishman W, Smithen C, Befler B, Kligfield P, Killip T. Noninvasive assessment of clinical response to oral propranolol therapy. Am J Cardiol 1975;35:635–644.PubMedCrossRefGoogle Scholar
  40. 40.
    Sadick NN, Tan ATH, Fletcher PJ, Morris J, Kelly DT. A double-blind randomized trial of propranolol and verapamil in the treatment of effort angina. Circulation 1982;66:574–579.PubMedCrossRefGoogle Scholar
  41. 41.
    Johnston DL, Gebhardt VA, Donald A, Kostuk WJ. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: A double-blind, placebo-controlled, randomized, cross-over study with radionuclide ventriculography. Circulation 1983;68:1280–1289.PubMedCrossRefGoogle Scholar
  42. 42.
    Hung J, Lamb IH, Connolly SJ, Jutzy KR, Goris ML, Schroeder JS. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: A double-blind, randomized, and placebo-controlled study. Circulation 1983;68:560–569.PubMedCrossRefGoogle Scholar
  43. 43.
    Anderson JL, Wagner JM, Datz FL, Christian PE, Bray BE, Taylor AT. Comparative effects of diltiazem, propranolol and placebo on exercise performance using radionuclide ventriculography in patients with symptomatic coronary artery disease: Results a double-blind, randomized, cross-over study. Am Heart J 1984;107:698–695.PubMedCrossRefGoogle Scholar
  44. 44.
    Zacca NM, Verani MS, Chahine RA, Miller RR. Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hypoperfusion in stable angina. Am J Cardiol 1982;50:689–695.PubMedCrossRefGoogle Scholar
  45. 45.
    Gibbons RJ, Lavie CJ, Zinsmeister AR, Gersh BJ. Exercise assessment after myocardial infarction-long term changes in patients selection (abstract). J Am Coll Cardiol 1988;11:122.CrossRefGoogle Scholar
  46. 46.
    Khaja F, Walton JA Jr, Brymer JF, Lo E, Osterberger L, O’Neill WW, Cocfer HT, Weiss R, Lee T, Kurian T, Goldberg D, Pitt P, Golstein S. Intracoronary fibrinolytic therapy in acute myocardial infarction: Report of a prospective randomized trial. N Engl J Med 1983;308:1305–1311.PubMedCrossRefGoogle Scholar
  47. 47.
    Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE, Chew PH, Gottlieb SH, Halperin HR, Ouyang P, Walford GD, Bell WR, Fatterpaker AK, Llevellyn M, Topol ES, Healy B, Siu CO, Becker LC. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987;317:1613–1618.PubMedCrossRefGoogle Scholar
  48. 48.
    O’Rourke M, Baron D, Keogh A, Kelly R, Nelson G, Barnes C, Rattos J, Graham K, Hillman K, Newman H, Healey J, Woolridge J, Rivers J, White H, Withlock R. Limitations of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988;77:1311–1315.PubMedCrossRefGoogle Scholar
  49. 49.
    Wackers FJ, Berger HJ, Weinberg MA, Zaret BL. Spontaneous changes in left ventricular function over the first 24 hours of acute myocardial infarction: Implications for evaluation therapeutic interventions. Circulation 1982;66:748–754.PubMedCrossRefGoogle Scholar
  50. 50.
    L’Abbate A, Biagini A, Michelassi C, Maseri A. Myocardial kinetics of thallium and potassium in man. Circulation 1979;57:776–785.CrossRefGoogle Scholar
  51. 51.
    Bellet GA, Watson DD. Myocardial thallium-201 kinetics in ischemia and infarction. Progr NUCI. Med 1980;6:35–41.Google Scholar
  52. 52.
    Kiat H, Berman DS, Maddahi J, De Yang L, Van Train K, Rozanski A, Friedman JD. Late reversibility of tomographic myocardial thallium defects: An accurate marker of myocardial viability. J Am Coll Cardiol 1988;12:1456–1463.PubMedCrossRefGoogle Scholar
  53. 53.
    Yang LD, Berman DS, Kiat H, Resser KJ, Friedman JD, Rozanski A, Maddahi J. The frequency of late reversibility in SPECT thallium-201 stress-redistribution studies. J Am Coll Cardiol 1990;15:,334–340.PubMedCrossRefGoogle Scholar
  54. 54.
    Dilsizian V, Rocco TP, Freedman N, Leon M, Bonow RO. Enhanced detection of ischemic but viable myocardium reinjection after stress-redistribution imaging. N Engl J Med 1990;323:141–146.PubMedCrossRefGoogle Scholar
  55. 55.
    Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluoro-deoxyglucose. Circulation 1991;83:26–37.PubMedCrossRefGoogle Scholar
  56. 56.
    Bonow RO, Dilsizian V. Thallium-201 for assessment of myocardial viability. Semin Nucl Med 1991;21:230–237.PubMedCrossRefGoogle Scholar
  57. 57.
    Watson DD. Thallium-201 reinjection: Truth or artifact? J Nucl Biol Med 1992;36:15–21.PubMedGoogle Scholar
  58. 58.
    Beller GA, Sinusas AJ. Experimental studies of the physiologic properties of technetium-99m isonitriles. Am J Cardiol 1991;66:5E–8E.CrossRefGoogle Scholar
  59. 59.
    Beanlands RS, Dawood F, Wen W, McLaughlin PR, Butany J, D’Amati G, Liu PT. Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability? Circulation 1990;82:1802–1814.PubMedCrossRefGoogle Scholar
  60. 60.
    Marzullo P, Parodi O, Reisenhofer B, Sambuceti G, Picano E, Distante A, Gimelli A, L’Abbate A. Value of rest thallium-201/tc-99m sestamibi scans and dobutamine echocardiography for detection myocardial viability. Am J Cardiol 1993;71:166–172.PubMedCrossRefGoogle Scholar
  61. 61.
    De Coster PM, Melin JA, Detry JMR, Brasseur LA, Beckers C, Col J. Coronary artery perfusion in acute myocardial infarction: Assessment by pre-and post intervention thallium-201 myocardial perfusion imaging. Am J Cardiol 1985;55:889–895.PubMedCrossRefGoogle Scholar
  62. 62.
    Maddahi J, Ganz W, Ninomiya K, Hashida J, Fishbein MC, Mondkar A, Buchbinder N, Marcus M, Geft I, Shah P, Rozanski A, Swan HJC, Berman DS. Myocardial salvage in intracoronary thrombolysis in evolving acute myocardial infarctions: Evaluation using intracoronary injection of thallium-201. Am Heart J 1981;102:664–675.PubMedCrossRefGoogle Scholar
  63. 63.
    Weiss AT, Maddahi J, Lew AS, Shah PK, Ganz W, Swan HJC, Berman DS. Reverse redistribution of thallium-201: A sign of non-transmural myocardial infarction with patency of the infarct-related coronary artery. J Am Coll Cardiol 1986;17:61–67.CrossRefGoogle Scholar
  64. 64.
    Wackers FJ. Thrombolytic therapy for myocardial infarction: Assessment of efficacy by myocardial perfusion imaging with technetium-99m Sestamibi. Am J Cardiol 1991;66:36E–41E.CrossRefGoogle Scholar
  65. 65.
    Verani MS, Jeroudi MO, Mahmarian JJ, Boyce TM, Borges-Neto S, Patel B, Bolli R. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyi-sobutyl isonitrile. J Am Coll Cardiol 1988;12:1573–1581.PubMedCrossRefGoogle Scholar
  66. 66.
    Santoro GM, Bisi G, Sciagra R, Leoncini M, Fazzini PF, Meldolesi U. Single photon emission computed tomography with technetium-99m hexakis 2-methoxyisobutyl isonitrile in acute myocardial infarction before and after thrombolytic treatment: Assessment of salvaged myocardium and prediction of late functional recovery. J Am Coll Cardiol 1990;15:301–314.PubMedCrossRefGoogle Scholar
  67. 67.
    Gibson RS, Watson DD, Craddock GB, Crampton RS, Kaiser DL, Denny ML, Beller GA. Prediction of cardiac events after uncomplicated myocardial infarction: Prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation 1983;68:321–336.PubMedCrossRefGoogle Scholar
  68. 68.
    Leppo JA, O’Brien J, Rothendler JA, Getchell JD, Lee VW. Dipyridamole-thallium-201 scintigraphy in the prediction of future cardiac events after myocardial infarctions. N Engl J Med 1984;310:1014–1018.PubMedCrossRefGoogle Scholar
  69. 69.
    Cuocolo A, Pace L, Ricciardelli B, Chiarelli B, Trimarco B, Salvatore M. Identification of viable myocardium in patients with chronic coronary artery disease: Comparison of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyiso-butyl isonitrile. J Nucl Med 1992;33:505–515.PubMedGoogle Scholar
  70. 70.
    Marcassa C, Galli M, Parodi O, Marzullo P, Pirelli S, Inglese E, Giubbini R, Verna E, Santoro GM, Bisi G, Sambuceti G. Maldistribution of regional myocardial perfusion at rest in patients with coronary artery disease and no previous myocardial infarction evidenced by 99m-Tc sestamibi scintigraphy. J Nucl Biol Med, 1994, in press.Google Scholar
  71. 71.
    Marzullo P. Myocardial hibernation and viability: A new challenge for cardiac imaging. Prim Cardiol, 1994, in press.Google Scholar
  72. 72.
    Wheelan K, Wolfe C, Corbett J, Rude RE, Winni-ford M, Parkey RW, Buja LM, Willerson JT. Early positive technetium-99m stannous pyrophosphate images as a marker of reperfusion after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1985;56:252–256.PubMedCrossRefGoogle Scholar
  73. 73.
    Wolfe CL, Lewis SE, Corbett J, Buja LM, Willerson JT. Measurement of myocardial infarction fraction using single photon emission computed tomography. J Am Coll Cardiol 1985;6:145–151.PubMedCrossRefGoogle Scholar
  74. 74.
    Khaw BA, Gold HK, Leinback RL, Fallon JT, Strauss W, Pohost GM, Haber H. Early imaging of experimental myocardial infarction by intracoronary administration of 131-I-labelled anticardiac myosin (Fab’)2 fragments. Circulation 1978;58:1137–1142.PubMedCrossRefGoogle Scholar
  75. 75.
    Schwaiger M, Brunken R, Grover-McKay M, Krivokapich J, Child J, Tillish JH, Phelps ME, Schelbert HR. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol 1986;8:800–808.PubMedCrossRefGoogle Scholar
  76. 76.
    Schwaiger M, Brunken R, Knvokapich J, Child J, Tillish JH, Phelps ME, Schelbert HR. Beneficial effect of residual antegrade flow on tissue viability as assessed by positron emission tomography in patients with myocardial infarction. Eur Heart J 1987;8:981–988.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Paolo Marzullo
  • Alessia Gimelli
  • Antonio L’Abbate

There are no affiliations available

Personalised recommendations